A New Perspective on the Anti-Suicide Effects With Ketamine Treatment
Authors:
- Yena LeeYLYena Lee
- Kahlood SyedaKSKahlood Syeda
- Nadia A. MaruschakNMNadia A. Maruschak
- Danielle S. ChaDCDanielle S. Cha
- Rodrigo B. MansurRMRodrigo B. Mansur
- Ida K. Wium-AndersenIWIda K. Wium-Andersen
- Hanna O. WoldeyohannesHWHanna O. Woldeyohannes
- Joshua D. RosenblatJRJoshua D. Rosenblat
- Roger S. McIntyreRMRoger S. McIntyre
- 1 February 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (1) , 50-56
Abstract
Available evidence indicates that a single, low-dose administration of ketamine is a robust, rapid-onset intervention capable of mitigating depressive symptoms in adults with treatment-resistant mood disorders. Additional evidence also suggests that ketamine may offer antisuicide effects. Herein, we propose that the antidepressant effects reported with ketamine administration are mediated, in part, by targeting neural circuits that subserve cognitive processing relevant to executive function and cognitive emotional processing. Empirical support for the conceptual framework of the cognitive domain as a critical target of ketamine's action is the additional observation that pretreatment cognitive function predicts treatment outcomes with ketamine administration. The proposal that beneficial effects on cognitive function may be, in some individuals, the proximate mechanism mitigating symptom relief in mood disorders exists alongside the well-established deleterious effect of ketamine on cognitive function. During the past 5 years, there have been several reviews and meta-analyses concluding that ketamine has possible clinical benefits in refractory mood disorders. We introduce the conceptual framework that ketamine's salutary effects, notably in suicidality, may in part be via procognitive mechanisms.Keywords
This publication has 58 references indexed in Scilit:
- Antidepressant Utilization and Suicide in Europe: An Ecological Multi-National StudyPLOS ONE, 2013
- Targeting the Glutamatergic System to Treat Major Depressive DisorderDrugs, 2012
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responsesNature, 2011
- Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress ExposureBiological Psychiatry, 2011
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar DepressionArchives of General Psychiatry, 2010
- Emerging role of glutamate in the pathophysiology of major depressive disorderBrain Research Reviews, 2009
- The sales of antidepressants and suicide rates in Norway and its counties 1980–2004Journal of Affective Disorders, 2007
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major DepressionArchives of General Psychiatry, 2006
- A Neurotrophic Model for Stress-Related Mood DisordersBiological Psychiatry, 2006
- Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in HumansJournal of Pharmaceutical Sciences, 1982